enGene Therapeutics Inc. ENGN

ENGN Company Overview

enGene Therapeutics Inc. is a clinical-stage biotechnology company focused on developing non-viral genetic medicines for diseases with high unmet medical need, with an initial emphasis on urologic cancers. The company operates within the biotechnology and oncology sectors and is primarily focused on localized delivery of gene-based therapies using its proprietary delivery platform. Its lead development programs are directed toward non-muscle invasive bladder cancer (NMIBC), particularly in patients who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy.

The company’s core value proposition centers on its proprietary Deterministic Transport Vector (DTV) platform, a non-viral nanoparticle technology designed to deliver genetic payloads directly into mucosal tissues. enGene’s lead product candidate, detalimogene voraplasmid (also known as EG-70), is designed to locally express multiple immunomodulatory proteins in bladder tissue. The company evolved from earlier platform research in gene delivery technologies and became publicly traded on Nasdaq through a business combination completed in 2023. Its strategic positioning is based on localized gene therapy delivery intended to reduce systemic toxicity while enhancing therapeutic activity in difficult-to-treat cancers.